The Merger/License Dance of AstraZeneca, Forest and Novexel
This article was originally published in Start Up
Executive Summary
As public health officials warn about new strains of resistant bacteria spreading in hospitals, drug firms have been slow to produce new ammunition. But the past few years have seen a spate of deals, both licenses and acquisitions, among firms maneuvering into the antibiotic space. The latest antibiotic deal-AstraZeneca PLC's two-step, $350 million acquisition of Novexel SA--happened just before the winter holidays and was easy to overlook amid the year-end flurry of industry action. It's worth revisiting for a few reasons.
You may also be interested in...
AZ Spins Out Entasis To Tackle Resistant Infections
AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.
At PSA, Meet The New Deal-Makers (Part 2)
At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.
At PSA, Meet The New Deal-Makers (Part 2)
At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.